Don't Recommend a Flozin Plus GLP-1 Agonist for Most Diabetes Patients

July 2018

Buzz about CV benefits with SGLT2 inhibitors (Jardiance, etc) or GLP-1 agonists (Victoza, etc) will spark curiosity about COMBINING them.

Jardiance (empagliflozin) or Victoza (liraglutide) reduces both CV risk and death in type 2 diabetes.

This sets them apart from other diabetes meds. For example, so far Invokana (canagliflozin) or Ozempic (semaglutide) only lowers CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Sunscreens Help Balance Competing Concerns About Sunscreens
Aspirin Put the Aspirin and NSAID Interaction in Perspective
Diabetes Don't Recommend a Flozin Plus GLP-1 Agonist for Most Diabetes Patients
Women's Health Consider Both Mom and Baby When Treating Hypertension in Pregnancy
Crohn's Disease Be Ready When Your Crohn's Disease Patients Start Biologics
Stroke Optimize Meds to Reduce Recurrent Stroke Risk
Psychiatry Recommend Bipolar Treatment Based on the New Guideline Ranking System
Practice Set Patient Expectations for Home Genetic Tests
Communication Improve Communication With Older Patients
Anticoagulants Reassure Patients That Liver Injury With Oral Anticoagulants Is Rare